LIXTW (Lixte Biotechnology Holdings) Moat Score: 3/10 (As of Sep. 09, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LIXTW Lixte Biotechnology Holdings Inc LIXTW
34 GF Score
Price $0.02
! 1 Warning Sign
View Full Analysis

What is Lixte Biotechnology Holdings Moat Score?

Lixte Biotechnology Holdings LIXTW +4.74% 34 Moat Score is 3 as of Sep. 09, 2026. GuruFocus rates LIXTW with a GF Score™ of 34/100. The stock has 1 warning sign investors should review. Among 3,023 Industrial Products companies, Lixte Biotechnology Holdings ranks better than 91.8% on this metric.

Lixte Biotechnology Holdings has the Moat Score of 3, which implies that the company might have No Moat - Very weak/transient advantages.

Lixte Biotechnology Holdings has No Moat: Lixte Biotechnology Holdings Inc operates in a highly competitive biotech sector with limited market share and no significant cost advantages. The company lacks strong brand recognition, customer loyalty, and regulatory barriers that could provide a sustainable competitive edge.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Lixte Biotechnology Holdings might have No Moat - Very weak/transient advantages.

Lixte Biotechnology Holdings  (NAS:LIXTW) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Lixte Biotechnology Holdings Moat Score Related Terms

LIXTW vs CBAT, TGEN, STI: Moat Score Comparison

For the Electrical Equipment & Parts subindustry, Lixte Biotechnology Holdings's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lixte Biotechnology Holdings Moat Score vs Industrial Products Industry

For the Industrial Products industry and Industrials sector, Lixte Biotechnology Holdings's Moat Score distribution charts can be found below:

* The bar in red indicates where Lixte Biotechnology Holdings's Moat Score falls into.


LIXTW
34GF Score
Lixte Biotechnology Holdings Inc LIXTW
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 3 mean?
Lixte Biotechnology Holdings (LIXTW) has a Moat Score of 3 as of Sep. 09, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Lixte Biotechnology Holdings ranks #248 out of 3023 companies in the Industrial Products industry, placing it in the top 8.2%.
Is Lixte Biotechnology Holdings' Moat Score too high?
Lixte Biotechnology Holdings' current Moat Score is 3. Based on the distribution chart, Lixte Biotechnology Holdings ranks #248 out of 3023 companies in the Industrial Products industry, which is in the top quartile — a strong position relative to peers. Overall, Lixte Biotechnology Holdings has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Lixte Biotechnology Holdings' Moat Score compare to CBAT and TGEN?
According to the Industrial Products industry distribution chart, Lixte Biotechnology Holdings ranks #248 out of 3023 companies for Moat Score. This places Lixte Biotechnology Holdings in the top 8% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for an Industrial Products company?
A good Moat Score depends on the Industrial Products industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. Lixte Biotechnology Holdings's current Moat Score is 3. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lixte Biotechnology Holdings stock overvalued right now?
Lixte Biotechnology Holdings (LIXTW) has a current Moat Score of 3. The current Moat Score is 3. Lixte Biotechnology Holdings' overall GF Score™ is 34/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Lixte Biotechnology Holdings (LIXTW), the current Moat Score is 3 as of Sep. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Lixte Biotechnology Holdings Business Description

Other Exchanges LIXT:USA
Address 433 Plaza Real, Suite 275, Boca Raton, FL, USA, 33432
Lixte Biotechnology Holdings Inc is a clinical-stage biopharmaceutical and proton cancer therapy company focused on identifying new targets for cancer drug development and developing and commercializing cancer therapies. The company's drug product pipeline is focused on inhibitors of protein phosphatase 2A, which is used to enhance cytotoxic agents, radiation, immune checkpoint blockers and other cancer therapies. Its product is LB-100 for Ovarian Clear Cell Carcinoma and Metastatic Colon Cancer. The company operates in a single reportable segment, which consists of the development of cancer treatments.
34GF Score

Get the complete analysis for LIXTW

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.02
Price